Skip to main content
      RT @bella_mehta: KOA can not only ⬆️ morbidity, it also ⬆️s mortality - long term data from OAI - 5K pts, f/u 9

      Bella Mehta bella_mehta

      4 years ago
      KOA can not only ⬆️ morbidity, it also ⬆️s mortality - long term data from OAI - 5K pts, f/u 9 yrs . Greater KL scores (worse Xrays) - greater mortality! #ACR21 abst#1028 @RheumNow https://t.co/jREmbEN2Ae
      RT @doctorRBC: Exercise does not cause objective signs of increased disease activity in PsA
      ⭐️11 weeks of High Inten

      Robert B Chao, MD doctorRBC

      4 years ago
      Exercise does not cause objective signs of increased disease activity in PsA ⭐️11 weeks of High Intensity Interval Training in PsA pts did not show worsening changes in MRI SI joint bone marrow edema. Abs#1362 @RheumNow #ACRBest https://t.co/A3aOEy8Wz0 https://t.co/arPvjsbudm
      RT @MeralElRamahiMD: Clinical Pearl from Dr. @JKolfenbach
      ⭐️AAV doesn't typically cause hard palate lesions
      Instead

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Clinical Pearl from Dr. @JKolfenbach ⭐️AAV doesn't typically cause hard palate lesions Instead, consider: ➡️Cocaine-induced midline destructive lesion ➤try to send human neutrophil elastase ab (+ in cocaine use but not in AAV) ➡️Malignancy (NK T-cell lymphoma) #ACR21 @RheumNow https://t.co/KIEXgCR23c
      RT @drdavidliew: TNFi vs tofacitinib drug survival in RA
      (based on two Canadian registries, PS adjusted)

      This seems to

      David Liew drdavidliew

      4 years ago
      TNFi vs tofacitinib drug survival in RA (based on two Canadian registries, PS adjusted) This seems to be my refrain this ACR: 'TNF inhibitors: let's not forget, they're quite good' #ACR21 ABST1217 @RheumNow @Janetbirdope https://t.co/MyFc6do0JL
      RT @RichardPAConway: Dr Koster @MdWarrington @AliDuarteMD open label study baricitinib in relapsing GCA. Well-tolerated

      Richard Conway RichardPAConway

      4 years ago
      Dr Koster @MdWarrington @AliDuarteMD open label study baricitinib in relapsing GCA. Well-tolerated and allowed GC discontinuation by 24 weeks in most patients. Encouraging, we need an RCT! Abstr#1396 #ACR21 @RheumNow https://t.co/N2h54MHpIq
      FDA update: Voclosporin Safety in #SLE RCTs #ACR21 https://t.co/xWCBELxQIc

      Dr. John Cush RheumNow

      4 years ago
      FDA update: Voclosporin Safety in #SLE RCTs #ACR21 https://t.co/xWCBELxQIc
      FDA Safety Update - Dr. Nadia Habal reviewed approval of Voclosporin, anifrolumab, Avacopen and approved new indications

      Dr. John Cush RheumNow

      4 years ago
      FDA Safety Update - Dr. Nadia Habal reviewed approval of Voclosporin, anifrolumab, Avacopen and approved new indications for multiple drugs #ACR21 https://t.co/lAgQ4d0h2m
      FDA safety update: OA Stakeholder Workshop June 2021 - Congrats to FDA & AFfor tackling this LARGE unmet need- diffi

      Dr. John Cush RheumNow

      4 years ago
      FDA safety update: OA Stakeholder Workshop June 2021 - Congrats to FDA & AFfor tackling this LARGE unmet need- difficulty in determining benefit in OA (pain, structure, biomarkers?) -more research needed #ACR21 https://t.co/hCWU8OL0Le
      FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19:
      1. RECOVERY - lower mortality
      2. EMPACTA - Less progre

      Dr. John Cush RheumNow

      4 years ago
      FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19: 1. RECOVERY - lower mortality 2. EMPACTA - Less progression to mech vent or death 3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej
      FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showin

      Dr. John Cush RheumNow

      4 years ago
      FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH
      FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically i

      Dr. John Cush RheumNow

      4 years ago
      FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically important during COVID-19) Session 8M115 https://t.co/DqmxEIdvWZ D https://t.co/6aQG8yP7RW
      RT @Yuz6Yusof: #ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC:
      ⬇️Titres of Ab

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC: ⬇️Titres of Abs in SLE vs controls 💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA 📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9
      RT @RichardPAConway: Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect.

      Richard Conway RichardPAConway

      4 years ago
      Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
      RT @DrMiniDey: "Managing comorbidities can really improve outcomes for our patients"

      @UnaMakris highlights the bio-psyc

      Mrinalini Dey DrMiniDey

      4 years ago
      "Managing comorbidities can really improve outcomes for our patients" @UnaMakris highlights the bio-psycho-social approach to multicomplexity and multimorbidity in our older patients with RA. #ACR21 @RheumNow https://t.co/TMLqoreogZ
      RT @ericdeinmd: #ACR21 Gift of Gab https://t.co/R1e14UA0pQ
      Change habits through your words
      ⭐️Cost of inaction
      ⭐ï¸

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Gift of Gab https://t.co/R1e14UA0pQ Change habits through your words ⭐️Cost of inaction ⭐️Incremental change (ex ⬇️EtOH) ⭐️Follow the crowd! ⭐️Why not try? Good advice for persuading pts re behavior change, Rx adherence, smoking cessation, vax hesitancy, etc. @Rheumnow https://t.co/9Cd7hAafTr
      ×